Interactive Brokers shares jump as it secures spot in S&P 500
Karin Eastham, a director at Veracyte, Inc. (NASDAQ:VCYT), recently executed a series of stock transactions as disclosed in a recent SEC filing. The company, currently valued at $3.36 billion, has seen its stock surge nearly 95% over the past six months, trading near its 52-week high of $46. On January 2, Eastham sold a total of 10,000 shares of Veracyte common stock, generating proceeds of approximately $403,005. The shares were sold at prices ranging from $39.46 to $40.78.
Additionally, Eastham exercised stock options to acquire 10,000 shares at a price of $5.28 per share, which were subsequently sold as part of the transactions. Following these transactions, Eastham holds 18,497 shares of Veracyte common stock. These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on August 20, 2024.
In other recent news, Veracyte, Inc. reported record Q3 2024 revenues of $115.9 million, marking a 29% increase from the previous year, driven by strong performance in its testing business. The company also raised its total revenue guidance for 2024, reflecting confidence in its growth and market expansion plans. Goldman Sachs downgraded Veracyte's stock from Buy to Neutral and slightly decreased the price target to $37, citing a possible deceleration in Afrima growth in 2025. Despite this, Decipher Prostate is expected to remain a significant contributor to the company's revenue in the coming year.
On the other hand, Wolfe Research initiated coverage on Veracyte shares with an Outperform rating and a price target of $50.00, highlighting significant revenue growth and gross margin expansion since 2021. The firm anticipates high single-digit to low double-digit revenue growth and expects EBITDA margins to approach 30% over the next five years.
In other company developments, Veracyte has plans to expand Decipher into the metastatic prostate cancer market and launch a MRD test for bladder cancer in 2026. Despite anticipating a $6 million revenue headwind due to the pause in the Envisia test, the company remains optimistic about its future growth. These recent developments underscore Veracyte's continued growth trajectory and market expansion in the diagnostic testing industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.